Nadine Hartmann

Boehringer Ingelheim International GmbH, Germany

Boehringer Ingelheim International GmbH (Employment)

Poster(s):

• (P-392) Characteristics of Patients with Idiopathic Pulmonary Fibrosis (IPF) Initiating Nintedanib or Pirfenidone Treatment Compared with Untreated Patients in the US